Epithelial-to-mesenchymal transition, cell polarity and stemness-associated features in malignant pleural mesothelioma

Cancer Letters

Volumn 302, Issue 2, 2011, Pages 136-143

  Casarsa, Claudia ^a   Bassani, Niccolò ^b   Ambrogi, Federico ^b   Zabucchi, Giuliano ^a   Boracchi, Patrizia ^b   Biganzoli, Elia ^b   Coradini, Danila ^b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Cell polarity; Epithelial to mesenchymal transition; Malignant pleural mesothelioma; Stemness features

Indexed keywords

ARTICLE; CELL ACTIVATION; CELL LOSS; CELL POLARITY; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; STRUCTURE ANALYSIS; TISSUE SECTION; TISSUE STRUCTURE;

CELL POLARITY; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MESODERM; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 79951562482     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.01.009     Document Type: Article

References (60)

1. Robinson B.W., Lake R.A. Malignant mesothelioma. Lancet 2005, 366:397-408.
2. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
3. Tanos B., Rodriguez-Boulan E. The epithelial polarity program: machineries involved and their hijacking by cancer. Oncogene 2008, 27:6939-6957.
4. Assémat E., Bazellières E., Pallesi-Pocachard E., Le Bivic A., Massey-Harroche D. Polarity complex proteins. Biochim. Biophys. Acta 2008, 1778:614-630.
5. Humbert P.O., Dow L.E., Russell S.M. The scribble and par complexes in polarity and migration: friends or foes?. Trends Cell. Biol. 2006, 16:622-630.
6. Mazumdar A., Mazumdar M. How one becomes many: blastoderm cellularization in Drosophila melanogaster. BioEssays 2002, 24:1012-1022.
7. Wodarza A., Huttner W.B. Asymmetric cell division during neurogenesis in Drosophila and vertebrates. Mech. Dev. 2003, 120:1297-1309.
8. Brumby A.M., Richardson H.E. Scribble mutants cooperate with oncogenic Ras or Notch to cause neoplastic overgrowth in Drosophila. EMBO J. 2003, 22:5769-5779.
9. Januschke J., Gonzalez C. Drosophila asymmetric division, polarity and cancer. Oncogene 2008, 27:6994-7002.
10. Bilder D. Epithelial polarity and proliferation control: links from the Drosophila neoplastic tumor suppressors. Genes Dev. 2004, 18:1909-1925.
11. Huntly B.J.P., Gilliland D.G. Summing up cancer stem cells. Nature 2005, 435:1169-1170.
12. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
13. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
14. Cacciotti P., Barbone D., Porta C., Altomare D.A., Testa J.R., Mutti L., et al. SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res. 2005, 65:5256-5262.
15. Mani S.A., Guo W., Liao M.-J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
16. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9:265-273.
17. Gordon G.J., Rockwell G.N., Jensen R.V., Rheinwald J.G., Glickman J.N., Aronson J.P., et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am. J. Pathol. 2005, 166:1827-1840.
18. Chalifa-Caspi V., Yanai I., Ophir R., Rosen N., Shmoish M., Benjamin-Rodrig H., et al. Gene-Annot: comprehensive two-way linking between oligonucleotide array probesets and GeneCards genes. Bioinformatics 2004, 20:1457-1458.
19. Moreno-Bueno G., Portillo F., Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 2008, 27:6958-6969.
20. Hoenerhoff M.J., Chu I., Barkan D., Liu Z.-Y., Datta S., Dimri G.P., et al. BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene 2009, 28:3022-3032.
21. Liu M., Casimiro M.C., Wang C., Shirley L.A., Jiao X., Katiyar S., et al. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc. Natl. Acad. Sci. USA 2009, 106:19035-19039.
22. Jiang F., Qiu Q., Khanna A., Todd N.W., Deepak J., Xing L., et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol. Cancer Res. 2009, 7:330-338.
23. Chen Z., Liu F., Ren Q., Zhao Q., Ren H., Lu S., et al. Suppression of ABCG2 inhibits cancer cell proliferation. Int. J. Cancer 2010, 126:841-851.
24. I.T. Jolliffe, Principal Components Analysis, second ed., Springer-Verlag, New York, 2002.
25. Tibshirani R., Hastie T., Narashiman B., Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. USA 2002, 99:6567-6572.
26. Tesei A., Zoli W., Arienti C., Storci G., Granato A.M., Pasquinelli G., et al. Isolation of stem/progenitor cells from normal lung tissue of adult humans. Cell Prolif. 2009, 42:298-308.
27. Herrick S.E., Mutsaers S.E. The potential of mesothelial cells in tissue engineering and regenerative medicine applications. Int. J. Artif. Organs 2007, 30:527-540.
28. Hader C., Marlier A., Cantley L. Mesenchymal-epithelial transition in epithelial response to injury: the role of Foxc2. Oncogene 2010, 29:1031-1040.
29. Li G., Satyamoorthy K., Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 2001, 61:3819-3821.
30. Tomita K., van Bokhoven A., van Leenders G.J.L.H., Ruijter E.T.G., Jansen C.F.J., Bussemakers M.J.G., et al. Cadherin switching in human prostate cancer progression. Cancer Res. 2000, 60:3650-3654.
31. Hazan R.B., Phillips G.R., Qiao R.F., Norton L., Aaronson S.A. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion and metastasis. J. Cell. Biol. 2000, 148:779-790.
32. Nakajima S., Doi R., Toyoda E., Tsuji S., Wada M., Koizumi M., et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin. Cancer Res. 2004, 10:4125-4133.
33. Blanchards A.A., Skliris G.P., Watson P.H., Murphy L.C., Penner C., Tomes L., et al. 3 and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch. 2009, 454:647-656.
34. Resnick M.B., Konkin T., Routhier J.J., Sabo E., Pricolo V.E. Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod. Pathol. 2005, 18:511-518.
35. Leotlela P.D., Wade M.S., Duray P.H., Rhode M.J., Brown H.F., Rosenthal D.T., et al. Claudin-1 overexpression in melanoma is regulated by PKC and contribute to melanoma cell motility. Oncogene 2007, 26:3846-3856.
36. Kaihara T., Kusaka T., Nishi M., Kawamata H., Imura J., Kitajima K., et al. Dedifferentiation and decreased expression of adhesion molecules, E-cadherin and ZO-1, in colorectal cancer are closely related to liver metastasis. J. Exp. Clin. Cancer Res. 2003, 22:117-123.
37. Gort E.H., Suijkerbuijk K.P.M., Roothaan S.M., Raman V., Vooijs M., van der Wall E., et al. Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer. Cancer Epidemiol. Biomarkers Prev. 2008, 17:3325-3330.
38. Hung J.J., Yang M.H., Hsu H.S., Hsu W.H., Liu J.S., Wu K.J. Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and snail expression in resectable non-small cell lung cancer. Thorax 2009, 64:1082-1089.
39. Valdés-Mora F., Gómez del Pulgar T., Bandrés E., Cejas P., Ramírez de Molina A., Pérez-Palacios R., et al. TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer. Ann. Surg. Oncol. 2009, 16:78-87.
40. Lehmann J.M., Riethmuller G., Johnson J.P. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc. Natl. Acad. Sci. USA 1989, 86:9891-9895.
41. Zabouo G., Imbert A.-M., Jacquemier J., Finetti P., Moreau T., et al. CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res. 2009, 11:R1.
42. Wu G.J., Wu M.W., Wang S.W., Liu Z., Qu P., Peng Q., et al. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene 2001, 279:17-31.
43. Aldovini D., Demichelis F., Doglioni C., Di Vizio D., Galligioni E., Brugnara S., et al. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int. J. Cancer 2006, 119:1920-1926.
44. A. Sato, I. Torii, Y. Okamura, T. Yamamoto, T. Nishigami, T.R. Kataoka, et al., Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium, Mod. Pathol., 2010, doi:10.1038/modpathol.2010.134.
45. S.G. Jung, Y.D. Kwon, J.A. Song, M.J. Back, S.Y. Lee, C. Lee, et al., Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma, Cancer Sci., 2010 (June 9, Epub ahead of print).
46. Yeasmin S., Nakayama K., Rahman M.T., Rahman M., Ishikawa M., Iida K., et al. Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes. Gynecol. Oncol. 2010, 117:409-416.
47. Somlo G., Chu P., Frankel P., Ye W., Groshen S., Doroshow J.H., et al. Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome. Ann. Oncol. 2008, 19:1853-1859.
48. Kwon M.S., Lee Y.I., Lee K.Y. p21 as a prognostic factor in non-small cell lung carcinomas. Pathol. Res. Pract. 2006, 202:849-856.
49. Ogino S., Nosho K., Shima K., Baba Y., Irahara N., Kirkner G.J., et al. p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis. Cancer Epidemiol. Biomarkers Prev. 2009, 18:2513-2521.
50. Bienz M. β-Catenin: a pivot between cell adhesion and Wnt signalling. Curr. Biol. 2005, 15:R64-R67.
51. Fodde R., Brabletz T. Wnt/β-catenin signaling in cancer stemness and malignant behaviour. Curr. Opin. Cell. Biol. 2007, 19:150-158.
52. Shih I.M. The role of CD146 (Mel-CAM) in biology and pathology. J. Pathol. 1999, 189:4-11.
53. Bolos V., Grego-Bessa J., de la Pompa J.L. Notch signaling in development and cancer. Endocrine Rev. 2007, 28:339-363.
54. Wilson A., Radtke F. Multiple functions of Notch signaling in self-renewing organs and cancer. FEBS Lett. 2006, 580:2860-2868.
55. Cano A., Pérez-Moreno M.A., Rodrigo I., Locascio A., Blanco M.J., del Barrio M.G., et al. The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2000, 2:76-83.
56. Ohkubo T., Ozawa M. The transcription factor snail downregulates the tight junction components independently of E-cadherin downregulation. J. Cell. Sci. 2004, 117:1675-1685.
57. Vesuna F., van Diest P., Chen J.H., Raman V. Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem. Biophys. Res. Commun. 2008, 367:235-241.
58. Karreth F., Tuveson D.A. Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biol. Ther. 2004, 3:1058-1059.
59. Bidlingmaier S., He J., Wang Y., An F., Feng J., Barbone D., et al. Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res. 2009, 69:1570-1577.
60. Kristiansen G., Yu Y., Schlüns K., Sers C., Dietel M., Petersen I. Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer. Anal. Cell. Pathol. 2003, 25:77-81.